Skip to main content

Table 1 Clinico-pathological characteristics of patients

From: Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

Median age

48.1 years

Histological type

Infiltrating ductal carcinoma

SBR grade

 

   I

2 (10.5%)

   II

9 (47.3%)

   III

5 (26.3%)

   Not available

3 (15.7%)

Hormone receptors

 

   Positive HR

12 (63.1%)

   Negative HR

6 (31.5%)

   Not available

1 (5.2%)